| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa00a32b732c3976624e6b54d7f0c454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3e027020614a2f83d92564df41af9773
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e8d6d46c7439444f2ee053109f024e5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52a160b46696d69c46f084008a20d4a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41dfcae9f9f9032511926c1e85b875b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8359b0ecdc72ccbbcc596595f51f0d97
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_beaae3b27f75f58c1cfdd19259a144f5 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 |
| filingDate |
2008-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62df9419cba626be2186fa5fcfa2a1e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9e813d282c45132f3dbfbdd3a9524af
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17122c308f274ce986c2e347801069e8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2a246374efaea46033d797693fe0e4e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18a07462ed0120fb2472655ea0eeac8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_134ceb2967df923c287cdad976a8a330 |
| publicationDate |
2010-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010024493-A1 |
| titleOfInvention |
Preparation of the streptomyces strains producing alpha-glucosidase inhibitors transformed by the recombinant vectors harboring the salbostatin biosynthesis gene cluster, and mass-production method of these inhibitors |
| abstract |
Disclosed are the preparation of a novel strain capable of producing an alpha-glucosidase inhibitor on the basis of a salbostatin biosynthetic gene cluster, and the mass-scale production of the alpha-glucosidase inhibitor. A 17-kb gene cluster, derived from the salbostatin-producing strain Streptomyces albus KCTC 9015, encoding 14 enzymes from sa1H to salU, is cloned into an expression vector which is then transformed into a Streptomyces strain in which the alpha-glucosidase inhibitors valienamine or valiolamine can be thus expressed in a large quantity. Thus, it allows diabetes drugs to be produced at low cost because valienamine or valiolamine are used as materials for their production. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113846041-A |
| priorityDate |
2008-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |